Source:http://linkedlifedata.com/resource/pubmed/id/10614716
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2000-1-13
|
pubmed:abstractText |
To utilize cytokine levels to predict sustained response (SR) to alpha interferon (IFN alpha) therapy in chronic hepatitis C patients, and to determine the relationship between serum tumor necrosis factor alpha (TNF alpha), interleukin (IL) IL 6, IL 8, IL 12, transforming growth factor beta (TGF beta 1) and the degree of liver damage as reflected by traditional markers.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0009-9120
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
537-45
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10614716-Adult,
pubmed-meshheading:10614716-Aged,
pubmed-meshheading:10614716-Female,
pubmed-meshheading:10614716-Hepatitis C, Chronic,
pubmed-meshheading:10614716-Humans,
pubmed-meshheading:10614716-Interferon-alpha,
pubmed-meshheading:10614716-Interleukins,
pubmed-meshheading:10614716-Liver,
pubmed-meshheading:10614716-Male,
pubmed-meshheading:10614716-Middle Aged,
pubmed-meshheading:10614716-Transforming Growth Factor beta,
pubmed-meshheading:10614716-Treatment Outcome
|
pubmed:year |
1999
|
pubmed:articleTitle |
Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.
|
pubmed:affiliation |
Sunnybrook and Women's Health Sciences Centre, Department of Pharmacology, University of Toronto, Ontario, Canada. manuela@srcl.sunnybrook.utoronto.ca
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|